Stuart Therapeutics has collected equity financing from investors including Wisconsin Alumni Research Foundation to fund phase 2 trials for a drug aimed at dry eye disease.
Stuart Therapeutics, a US-based biopharmaceutical company focused on ophthalmic diseases, completed an $11m series A round on Tuesday featuring Wisconsin Alumni Research Foundation, the tech transfer arm of University of Wisconsin-Madison.
InFocus Capital Partners led the round, which also featured Mimo Capital and Biobrit.
Founded in 2017, Stuart Therapeutics is working on treatments for a variety of diseases affecting the eye, such as glaucoma, dry and wet age-related macular degeneration and neurotrophic keratitis.
Its lead asset, ST-100,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.